Verastem, Inc. (VSTM) Stock Price & Analysis
Verastem, Inc. (VSTM) closed at USD 10.06 on Thursday, October 22, 2026, up 9.23% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 10.06; the Oct 22, 2026 session ranged USD 9.14–10.11 on volume of 5,947,095 shares. Market capitalization is —, with a 52-week range of USD 3.43–10.82 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VSTM.md
Key facts (VSTM)
- Last four reported quarters (through Jun 30, 2026): revenue $87.5M, net income -$203M (-231.6% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold VSTM (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $491K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 17.22 (range 12–24).
- Total return with dividends: 1Y +28.8% vs S&P 500 +14.9%; 5Y -67.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.44, revenue estimate $26.1M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VSTM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.6M | — | $10.0M | $30.9M | $87.5M |
| Operating income | -$61.4M | -$72.9M | -$92.1M | -$115M | -$170M | -$160M |
| Net income | -$71.2M | -$73.8M | -$87.4M | -$131M | -$209M | -$203M |
| EPS (diluted) | -$4.90 | -$4.57 | -$3.96 | -$3.66 | -$3.02 | — |
| Free cash flow | -$53.7M | — | — | -$105M | — | — |
| Operating margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% | -182.6% |
| Net margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% | -231.6% |
| Revenue growth | -97.7% | +26.4% | — | — | +209.1% | — |
| Cash + short-term investments | $100M | $87.9M | $137M | $88.8M | $205M | — |
| Total debt | $249K | $24.5M | $40.1M | $40.7M | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VSTM)
Superinvestors (SEC 13F-HR, Q2 2026) (VSTM)
1 of 80 tracked investors hold VSTM. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 0.25% | $1.8M | Added +59.7% |
Insider sales (SEC Form 4, open-market, last ~7 months) (VSTM)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Paterson Dan | President and CEO | 44,121 | $353K | 6.3% | Yes | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
| 2026-10-01 | Calkins Daniel | Chief Financial Officer | 2,566 | $21K | 2% | Yes | Routine (sold in Jan & Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
| 2026-09-21 | Calkins Daniel | Chief Financial Officer | 55 | $0K | 0% | Yes | Routine (sold in Jan & Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-08-03 | Paterson Dan | President and CEO | 1,302 | $8K | 0.2% | Yes | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-22 | Paterson Dan | President and CEO | 20,871 | $87K | 3.4% | Yes | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-22 | Calkins Daniel | Chief Financial Officer | 4,089 | $17K | 3.4% | Yes | Routine (sold in Jan & Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-05-04 | Paterson Dan | President and CEO | 806 | $5K | 0.1% | Yes | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (VSTM)
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 17.22 (low 12, high 24).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | BTIG | Reiterated | Buy | $24 |
| 2026-10-16 | Mizuho | Target raised | Outperform | $13 → $14 |
| 2026-10-15 | Jefferies | Target raised | Buy | $11 → $13 |
| 2026-10-15 | RBC Capital | Target raised | Outperform | $14 → $19 |
| 2026-10-15 | BTIG | Target raised | Buy | $18 → $24 |
| 2026-10-08 | BTIG | Reiterated | Buy | $18 |
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $18 |
| 2026-10-05 | BTIG | Reiterated | Buy | $18 |
| 2026-09-17 | Wolfe Research | Initiated | Outperform | |
| 2026-09-11 | HC Wainwright & Co. | Reiterated | Buy | $18 |
| 2026-09-11 | BTIG | Reiterated | Buy | $18 |
| 2026-08-11 | Mizuho | Target lowered | Outperform | $14 → $13 |
Total return (dividends reinvested) (VSTM)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +28.8% | -67.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +28.9% | -19.9% |
| Volatility (annualized) | 76.6% | 105.1% |
| Max drawdown | -67.6% (Nov 2025→Jun 2026) | -93.9% (Nov 2021→Aug 2024) |
VSTM revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $25.1M | 62.6% | +1073.5% |
| Copiktra License & Related Assets | $15.0M | 37.4% | — |
| Total revenue | $40.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
VSTM suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Pfizer (PFE) | “On July 11, 2012, we entered into a license agreement (the "Pfizer Agreement") with Pfizer under which Pfizer granted us worldwide, exclusive rights to research, develop, manufacture and commercialize products containing certain of Pfizer's inhibitors of FAK, including defactinib, for all therapeutic, diagnostic and prophylactic uses in humans.” |
| Partner | Secura Bio | “Under the terms of the asset purchase agreement with Secura, we are entitled to contingent consideration, including milestone payments and royalties, dependent upon the further development and commercial success of COPIKTRA.” |
| Partner | Oxford Finance | “Interest expense reflects interest expense due on our Loan Agreement with Oxford and our convertible notes, interest expense related to vendor financing arrangements, as well as non-cash interest related to the amortization of debt discount and issuance costs.” |
| Partner | Chugai Pharmaceutical | “On January 7, 2020, we entered into a license agreement with Chugai (the "Chugai Agreement") whereby Chugai granted us an exclusive worldwide license for the development, commercialization, and manufacture of products containing avutometinib.” |
| Partner | CSPC Pharmaceutical Group | “We have financed our operations to date primarily through public and private offerings of our common stock, pre-funded warrants and warrants, offerings of convertible notes, sales of common stock under our at-the-market equity offering program, our Note Purchase Agreement, former loan agreements, the upfront payments and milestone payments under our license and collaboration agreements with Sanofi, CSPC, and Yakul…” |
| Partner | Yakult Honsha | “We have financed our operations to date primarily through public and private offerings of our common stock, pre-funded warrants and warrants, offerings of convertible notes, sales of common stock under our at-the-market equity offering program, our Note Purchase Agreement, former loan agreements, the upfront payments and milestone payments under our license and collaboration agreements with Sanofi, CSPC, and Yakul…” |
| Partner | AMGEN INC (AMGN) | “In September 2021, we entered into a clinical collaboration agreement with Amgen, Inc. ("Amgen") to evaluate avutometinib in combination with Amgen's KRAS G12C inhibitor LUMAKRAS® (sotorasib) with and without defactinib in a Phase1/2 study entitled RAMP 203 in patients naïve to or previously treated with a KRAS G12C inhibitor.” |
| Competitor | Eli Lilly (LLY) | “Other competitors developing KRAS G12D inhibitors and pan-KRAS inhibitors are Astellas Pharma Inc., AstraZeneca, Bayer, BeOne, Boehringer Ingelheim, Chugai, D3 Bio, Eli Lilly, GenFleet, Genentech, Incyte Corporation, Jacobio, Jiangsu Hengrui Pharmaceuticals Company Ltd, Quanta Therapeutics, Ranok Therapeutics, Revolution Medicine, and Tyligand Bioscience; however, we are not aware of any FDA-approved treatments fo…” |
Quoted from the company's 10-K filed Mar 4, 2026.
VSTM company outlook (results filed Oct 14, 2026)
- “Under his leadership, the Company achieved accelerated FDA approval and commercial launch of AVMAPKI FAKZYNJA CO-PACK, while advancing VS-7375 into the clinic and rapidly towards a Phase 3 trial in metastatic pancreatic cancer in the first-line setting, which is expected to begin later this year.”
Quoted word-for-word from the SEC 8-K results press release.
VSTM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.44 | $-0.37 | +17.9% | $26.1M | 2 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.35 | +10.0% | $29.8M | 2 |
| Current fiscal year (ends Dec 2026) | $-1.80 | $-1.56 | +15.6% | $111.3M | 1 |
| Next fiscal year (ends Dec 2027) | $-1.22 | $-1.16 | +5.2% | $159.2M | 1 |
VSTM options: expected move
Options price a move of about ±19.1% (±$1.90) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±13.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 84.6% | ±19.1% |
| Dec 18, 2026 | 56 | 118.9% | ±36.1% |
| Jan 15, 2027 | 84 | 146.9% | ±51.2% |
| Mar 19, 2027 | 147 | 99.2% | ±48.9% |
| Jun 17, 2027 | 237 | 88.4% | ±54.5% |
30-day implied volatility 85.8% vs 85.5% realized over the last 30 trading days. Put/call ratio (volume) 0.15. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 10.06 |
|---|---|
| Change | ▲ 9.23% (up) |
| Previous Close | USD 10.06 |
| Open | USD 10.06 |
| Day Range | USD 9.14 – 10.11 |
| 52-Week Range | USD 3.43 – 10.82 |
| Volume | 5,947,095 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (VSTM)
Nexqual's technical model rates VSTM "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.8 (neutral) |
| vs SMA50 | Above (USD 7.81) |
| MACD | 0.46 (positive) |
Analyst Ratings (VSTM)
Wall Street analysts rate VSTM "Buy" based on 10 analysts, with a mean price target of USD 17.22 (range USD 12–24), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 17.22 |
| High Target | USD 24 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (VSTM)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $26.08M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.31 vs est -0.45 ▲ beat |
| 2026-03-31 | USD -0.43 vs est -0.47 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.5 ▲ beat |
| 2025-09-30 | USD -0.54 vs est -0.61 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (VSTM)
| Total Revenue | $87.53M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1775.40% |
| Gross Margin | +87.64% |
| Operating Margin | -81.62% |
| Profit Margin | -231.59% |
| ROE | -471.16% |
| Debt / Equity | 1.69 |
| Current Ratio | 2.26 |
| Total Cash | $136.35M |
| Total Debt | $84.33M |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Ownership (VSTM)
| Insider Ownership | +0.81% |
|---|---|
| Institutional Ownership | +82.49% |
| Shares Outstanding | 90.56M |
| Float | 79.89M |
| Short % of Float | +16.62% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (VSTM)
Verastem, Inc. is led by Daniel W. Paterson, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| President, CEO & Director | Daniel W. Paterson |
|---|---|
| Chief Financial Officer | Daniel Calkins |
| President of Development & Director | Michael Glen Kauffman |
| Executive Vice President of Portfolio Strategy & Operations | Lori Horvat |
| Chief Scientific Officer | Jonathan Pachter |
Major Backers & Investors (VSTM)
Notable institutional backers of Verastem, Inc. include Armistice Capital, LLC, RTW Investments LP, Deep Track Capital, Lp, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 7.76% |
| RTW Investments LP | 7.33% |
| Deep Track Capital, Lp | 6.34% |
| Rosalind Advisors, Inc. | 4.4% |
| Nantahala Capital Management, LLC | 3.96% |
| Stonepine Capital Management, LLC | 3.7% |
| Fidelity | 1.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.15% |
| Vanguard Group | 7.86% |
| State Street | 5.67% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From Verastem, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Verastem initiated a rolling New Drug Application ("NDA") in May 2024 and aligned with the FDA on plans to complete the NDA submission in October 2024 for adult patients with KRAS-mutated recurrent LGSOC, who received at least one prior systemic therapy.
- Prior to NDA acceptance, the FDA granted Breakthrough Therapy Designation ("BTD") for the combination therapy for patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in May 2021.
- We have exclusively licensed a patent portfolio of four patent families that are owned or exclusively licensed by Chugai and therefore we have an exclusive option to exclusively license either directly from Chugai or from any party that has an exclusive license from Chugai.
- We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture, and any other aspects of inventions that are commercially important to the development of our business.
Partnerships
- We received the first "Therapeutic Accelerator Award" from Pancreatic Cancer Network ("PanCAN") for up to $3.8 million to support the RAMP 205 study.
- On January 7, 2020, we entered into a license agreement with Chugai (the "Chugai Agreement") whereby Chugai granted us an exclusive worldwide license for the development, commercialization, and manufacture of products containing avutometinib.
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to Achieving Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt